Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.48 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | WEE1 | P30291 | 2/20 | 0.44 |
| ▸ | PAK3 | O75914 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035605 | 0.88 | TNK2 (0.47) | RIPK2NOD2ACVR1TNK2EGFR | |
| SCHEMBL15041826 | 0.87 | JAK2 (0.46) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15041589 | 0.87 | JAK2 (0.45) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035615 | 0.87 | JAK2 (0.45) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035603 | 0.87 | JAK2 (0.47) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035599 | 0.86 | CDK4 (0.49) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035606 | 0.85 | JAK2 (0.48) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035600 | 0.84 | JAK2 (0.47) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035609 | 0.83 | PAK3 (0.66) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15035981 | 0.81 | PKN1 (0.59) | RIPK2NOD2ACVR1PAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | JAK2 227/4885BRD4 711/4885JAK3 525/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | JAK2 720/4885BRD4 1003/4885JAK3 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.